Yahoo
KSE - Delayed Quote KRW

JW Pharmaceutical Corporation (001067.KS)

49,100.00 -500.00 (-1.01%)
At close: November 2 at 3:30:22 PM GMT+9
Chart Range Bar
Loading chart for 001067.KS
  • Previous Close 49,600.00
  • Open 0.00
  • Bid --
  • Ask --
  • Day's Range 0.00 - 0.00
  • 52 Week Range 0.00 - 61,500.00
  • Volume 0
  • Avg. Volume 45
  • Market Cap (intraday) 1.117T
  • Beta (5Y Monthly) 1.05
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date (est.) --
  • Forward Dividend & Yield 650.00 (1.31%)
  • Ex-Dividend Date Mar 31, 2026
  • 1y Target Est --

JW Pharmaceutical Corporation manufactures and sells medicines and medical supplies in Japan and internationally. It offers products in the areas of cancer, immunological disease, cardiovascular system and metabolic diseases, regenerative medicine, eye diseases, and pancreatic cancer. The company also provides infant care system, gynecological examining table, operating room equipment, steam sterilizer, and other equipment. In addition, it offers wound care, pain care, and beauty care related products. The company was founded in 1945 and is based in Gwacheon-si, South Korea.

www.jw-pharma.co.kr

1,049

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .

YTD Return

001067.KS
18.16%
KOSPI Composite Index (^KS11)
39.03%

1-Year Return

001067.KS
16.65%
KOSPI Composite Index (^KS11)
42.64%

3-Year Return

001067.KS
17.63%
KOSPI Composite Index (^KS11)
150.05%

5-Year Return

001067.KS
2.74%
KOSPI Composite Index (^KS11)
94.43%

Earnings Trends

View More

Earnings Per Share

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY25
Revenue 191.1B
Earnings -1.87B
Profit Margin -0.98%

Q3

FY24

Q4

FY24

Q1

FY25

Q2

FY25

0
50B
100B
150B
0.0%
2.0%
4.0%
6.0%
8.0%
10.0%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    12.34%

  • Return on Assets (ttm)

    10.78%

  • Return on Equity (ttm)

    27.63%

  • Revenue (ttm)

    820.86B

  • Net Income Avi to Common (ttm)

    94.32B

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    102.08B

  • Total Debt/Equity (mrq)

    17.50%

  • Levered Free Cash Flow (ttm)

    66.53B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: